Silexion Therapeutics Corp SEC filings SLXNW
Silexion Therapeutics Corp has 279 filings in SEC EDGAR's recent list, going back to May 9, 2024. Its latest annual report, Form 10-K, was filed on Mar 17, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Oct 26, 2026 (bylaw or fiscal year change, shareholder vote results). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Aug 11, 2026 | — |
| EFFECT | Filing | Jun 18, 2026 | — |
| CORRESP | Letter to the SEC | Jun 16, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 15, 2026 | — |
| EFFECT | Filing | May 11, 2026 | — |
| EFFECT | Filing | May 11, 2026 | — |
| DRS | Filing | Mar 17, 2026 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 30, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2025 | — |
| EFFECT | Filing | Sep 11, 2025 | — |
| CORRESP | Letter to the SEC | Sep 9, 2025 | — |
| CORRESP | Letter to the SEC | Sep 9, 2025 | — |
| EFFECT | Filing | Sep 4, 2025 | — |
| CORRESP | Letter to the SEC | Sep 2, 2025 | — |
| UPLOAD | Letter from the SEC | Aug 28, 2025 | — |
| D | Filing | Aug 11, 2025 | — |
| EFFECT | Filing | May 29, 2025 | — |
| EFFECT | Filing | May 1, 2025 | — |
| AW | Filing | Apr 29, 2025 | — |
| AW | Filing | Apr 29, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 28, 2025 | — |
| EFFECT | Filing | Apr 25, 2025 | — |
| DRS | Filing | Apr 23, 2025 | — |
| EFFECT | Filing | Apr 1, 2025 | — |
| CORRESP | Letter to the SEC | Apr 1, 2025 | — |
| UPLOAD | Letter from the SEC | Feb 19, 2025 | — |
| EFFECT | Filing | Jan 15, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| CORRESP | Letter to the SEC | Jan 14, 2025 | — |
| UPLOAD | Letter from the SEC | Nov 5, 2024 | — |
| EFFECT | Filing | Oct 16, 2024 | — |
| UPLOAD | Letter from the SEC | Oct 15, 2024 | — |
| CORRESP | Letter to the SEC | Oct 15, 2024 | — |
| EFFECT | Filing | Sep 17, 2024 | — |
| CORRESP | Letter to the SEC | Sep 17, 2024 | — |
| UPLOAD | Letter from the SEC | Sep 16, 2024 | — |
| CERT | Filing | Aug 15, 2024 | — |
| 8-A12B | For registration of certain classes of securities | Aug 15, 2024 | — |
| 425 | Form 425 | Jul 25, 2024 | — |
| 425 | Form 425 | Jul 25, 2024 | — |
| EFFECT | Filing | Jul 16, 2024 | — |
| CORRESP | Letter to the SEC | Jul 15, 2024 | — |
| CORRESP | Letter to the SEC | Jul 12, 2024 | — |
| CORRESP | Letter to the SEC | Jul 5, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 3, 2024 | — |
| CORRESP | Letter to the SEC | Jun 24, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 5, 2024 | — |
Showing 48 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- SLXN (Nasdaq), SLXNW (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Cayman Islands
- Headquarters
- Ramat Gan, Israel
- SEC filer status
- , Emerging growth company
- SEC CIK
- 2022416
- Former names
- Biomotion Sciences (until Aug 15, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.